scPharmaceuticals Inc. (SCPH): Product News News

SCPH – Receives Complete Response Letter from the FDA for FUROSCIX.

Key Facts Surrounding This News Item

  • SCPH had returned -37.06% year-to-date leading up to today’s news, versus a +4.94% return from the benchmark S&P 500 during the same period.

More Info About scPharmaceuticals Inc. (SCPH)

scPharmaceuticals Inc. engages in the development and commercialization of transformative pharmaceutical products. The company’s under development products are for heart failure and infectious diseases that include Furoscix that is for treatment of worsening or decompensated heart failure outside of the inpatient setting. scPharmaceuticals Inc. formerly known as scPharmaceuticals LLC. and changed its name to scPharmaceuticals Inc. in March 2014. The company was founded 2013 and is based in Burlington, Massachusetts. View our full SCPH ticker page with ratings, news, and more.

SCPH at a Glance

SCPH Current POWR Rating™
Overall POWR Rating™
SCPH Current Price $3.70 0.27%
More SCPH Ratings, Data, and News

SCPH Price Reaction

The day of this event (Jun. 13, 2018)
SCPH Closing Price$5.93 22.08%
SCPH Volume953,000
899.96% from avg
Leading up to this event
SCPH 1-mo returnN/A%
After this event
SCPH 1-day return25.79%
SCPH 3-day return29.20%
SCPH 5-day return37.61%

SCPH Price Chart

The Top Stocks For 2019

More scPharmaceuticals Inc. (SCPH) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All SCPH News
Page generated in 0.7619 seconds.